MiR-106b and MiR-93 Regulate Cell Progression by Suppression of PTEN Via PI3K/Akt Pathway in Breast Cancer

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2017 May 19

PMID 28518139

Citations 100

Authors

Nana Li

Yuan Miao

Yujia Shan

Bing Liu

Yang Li

Lifen Zhao

Li Jia

Affiliations

Soon will be listed here.

Abstract

Accumulating evidences have revealed that dysregulated microRNAs (miRNAs) involve in the tumorigenesis, progression and even lead to poor prognosis of various carcinomas, including breast cancer. MiRNA-106b-5p (miR-106b) and miRNA-93-5p (miR-93) levels were confirmed to be significantly upregulated in breast cancer clinical samples (n=36) and metastatic cell line (MDA-MB-231) compared with those in the paired adjacent tissues and normal breast epithelial cell line (MCF-10A). Moreover, further research stated that the capability of migration, invasion and proliferation changed along with the altered expression of miR-106b and miR-93 in breast cancer. PTEN, the tumor-suppressor gene, was discovered to be reduced in breast cancer tissues or MDA-MB-231 cells with high levels of miR-106b and miR-93, which were inversely expressed in PTEN overexpression tissues or cells. Based on the investigation, miR-106b and miR-93 induced the migration, invasion and proliferation and simultaneously enhanced the activity of phosphatidylinositol-3 kinase (PI3K)/Akt pathway of MCF-7 cells, which could be blocked by upregulation of PTEN. Furthermore, suppression of PTEN reversed the function induced by anti-miR-106b and anti-miR-93 in MDA-MB-231 cells, indicating that PTEN was directly targeted by these miRNAs and acted as the potential therapeutic target for breast cancer therapy. In short, reductive PTEN mediated by miR-106b and miR-93 promoted cell progression through PI3K/Akt pathway in breast cancer.

Citing Articles

Integrative analysis of miRNA expression data reveals a minimal signature for tumour cells classification.

Napoletano S, Dannhauser D, Netti P, Causa F Comput Struct Biotechnol J. 2025; 27:233-242.

PMID: 39866665 PMC: 11760817. DOI: 10.1016/j.csbj.2024.12.023.

Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review.

Panda V, Mishra B, Mahapatra S, Swain B, Malhotra D, Saha S Cancers (Basel). 2025; 17(2).

PMID: 39858015 PMC: 11763662. DOI: 10.3390/cancers17020234.

PI3K/AKT/mTOR Targeting in Colorectal Cancer Radiotherapy: A Systematic Review.

Mousavikia S, Darvish L, Firouzjaei A, Toossi M, Azimian H J Gastrointest Cancer. 2025; 56(1):52.

PMID: 39849185 DOI: 10.1007/s12029-024-01160-1.

Predicting human miRNA disease association with minimize matrix nuclear norm.

Toprak A Sci Rep. 2024; 14(1):30815.

PMID: 39730483 PMC: 11680809. DOI: 10.1038/s41598-024-81213-4.

FNDC1 Facilitates Proliferation, Migration, and Invasion of Breast Cancer Cells Through Modulating Wnt/β-Catenin Pathway.

Fan G, Zhang C Biochem Genet. 2024; .

PMID: 39671143 DOI: 10.1007/s10528-024-10994-0.

References

Yen C, Su Z, Lee Y, Liu I, Yen C . miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2016; 22(22):5183-92. PMC: 4893465. DOI: 10.3748/wjg.v22.i22.5183. View

Fan L, Strasser-Weippl K, Li J, St Louis J, Finkelstein D, Yu K . Breast cancer in China. Lancet Oncol. 2014; 15(7):e279-89. DOI: 10.1016/S1470-2045(13)70567-9. View

Ke Z, Xu P, Shi Y, Gao A . MicroRNA-93 inhibits ischemia-reperfusion induced cardiomyocyte apoptosis by targeting PTEN. Oncotarget. 2016; 7(20):28796-805. PMC: 5045357. DOI: 10.18632/oncotarget.8941. View

Patel R, Gao M, Ahmad I, Fleming J, Singh L, Rai T . Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest. 2013; 123(3):1157-75. PMC: 3582117. DOI: 10.1172/JCI63672. View

Hudson R, Yi M, Esposito D, Glynn S, Starks A, Yang Y . MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene. 2012; 32(35):4139-47. PMC: 3530025. DOI: 10.1038/onc.2012.424. View

Du L, Zhao Z, Ma X, Hsiao T, Chen Y, Young E . miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene. 2013; 33(34):4307-15. PMC: 4281941. DOI: 10.1038/onc.2013.381. View

Fang L, Du W, Yang W, Rutnam Z, Peng C, Li H . MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle. 2012; 11(23):4352-65. PMC: 3552918. DOI: 10.4161/cc.22670. View

Vazquez F, Matsuoka S, Sellers W, Yanagida T, Ueda M, Devreotes P . Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proc Natl Acad Sci U S A. 2006; 103(10):3633-8. PMC: 1450134. DOI: 10.1073/pnas.0510570103. View

Hong W, Dong E . The past, present and future of breast cancer research in China. Cancer Lett. 2014; 351(1):1-5. DOI: 10.1016/j.canlet.2014.04.007. View

10.

DeSantis C, Siegel R, Bandi P, Jemal A . Breast cancer statistics, 2011. CA Cancer J Clin. 2011; 61(6):409-18. DOI: 10.3322/caac.20134. View

11.

Wu H, Zhu S, Mo Y . Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009; 19(4):439-48. PMC: 2664859. DOI: 10.1038/cr.2009.18. View

12.

Depowski P, Rosenthal S, Ross J . Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol. 2001; 14(7):672-6. DOI: 10.1038/modpathol.3880371. View

13.

Das S, Dixon J, Cho W . Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci U S A. 2003; 100(13):7491-6. PMC: 164614. DOI: 10.1073/pnas.0932835100. View

14.

Yan J, Zhang Y, Liao J, Ke K, Chang Y, Li P . MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1. Oncotarget. 2015; 6(30):29527-42. PMC: 4745744. DOI: 10.18632/oncotarget.5012. View

15.

Zheng L, Zhang Y, Liu Y, Zhou M, Lu Y, Yuan L . MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer. J Transl Med. 2015; 13:252. PMC: 4522974. DOI: 10.1186/s12967-015-0592-z. View

16.

Ren D, Jia L, Li Y, Gong Y, Liu C, Zhang X . ST6GalNAcII mediates the invasive properties of breast carcinoma through PI3K/Akt/NF-κB signaling pathway. IUBMB Life. 2014; 66(4):300-8. DOI: 10.1002/iub.1268. View

17.

Xiao X, Zhou L, Cao P, Gong H, Zhang Y . MicroRNA-93 regulates cyclin G2 expression and plays an oncogenic role in laryngeal squamous cell carcinoma. Int J Oncol. 2014; 46(1):161-74. DOI: 10.3892/ijo.2014.2704. View

18.

Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du W . MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8. Oncogene. 2010; 30(7):806-21. DOI: 10.1038/onc.2010.465. View

19.

Zheng L, Zhang Y, Lin S, Sun A, Chen R, Ding Y . Down-regualtion of miR-106b induces epithelial-mesenchymal transition but suppresses metastatic colonization by targeting Prrx1 in colorectal cancer. Int J Clin Exp Pathol. 2015; 8(9):10534-44. PMC: 4637578. View

20.

Choi N, Park J, Lee J, Yoe J, Park G, Kim E . miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression. Oncotarget. 2015; 6(27):23533-47. PMC: 4695135. DOI: 10.18632/oncotarget.4372. View